文献速递妇科

贝伐珠单抗在晚期低级别浆液性卵巢癌中的疗效:来自MITO 22试验的数据

Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial.
PubMed 文献 · Gynecol Oncol · 2023-03-23

该回顾性观察性多中心研究纳入MITO 22研究中128例晚期低级别浆液性卵巢癌患者,其中46例在一线或首次复发时接受贝伐珠单抗联合化疗。一线治疗中贝伐珠单抗联合化疗组(30例)中位无进展生存期为47.86个月,单纯化疗组(65例)为22.63个月(P=0.0392);复发治疗中贝伐珠单抗联合化疗组(16例)中位无进展生存期为37.1个月,铂类化疗组(33例)为11.22个月(P=0.013)。研究提示贝伐珠单抗在诊断时和复发时可能有效,但需进一步研究。

要点

  • 一线贝伐珠单抗联合化疗组中位PFS 47.86个月,单纯化疗组22.63个月(P=0.0392)。
  • 复发时贝伐珠单抗联合化疗组中位PFS 37.1个月,铂类化疗组11.22个月(P=0.013)。
  • 研究提示贝伐珠单抗在低级别浆液性卵巢癌诊断和复发时可能有效,需进一步研究。

核心结论

  • 研究提示贝伐珠单抗在低级别浆液性卵巢癌诊断时和复发时可能有效,这些数据需进一步研究。

研究设计与样本

  • 回顾性观察性多中心研究,描述MITO 22研究中接受化疗联合或不联合贝伐珠单抗的低级别浆液性卵巢癌患者的结局。
  • MITO 22研究共纳入128例患者,其中46例低级别浆液性卵巢癌患者在一线或首次复发时接受贝伐珠单抗。
  • 一线治疗中30例接受贝伐珠单抗联合化疗,65例接受单纯化疗;复发治疗中16例接受贝伐珠单抗联合化疗,33例接受铂类化疗。

主要发现

  • 一线治疗中,贝伐珠单抗联合化疗组中位无进展生存期为47.86个月(95%CI 31.48至未达到),单纯化疗组为22.63个月(95%CI 15至39.24),P=0.0392。
  • 复发治疗中,贝伐珠单抗联合化疗组中位无进展生存期为37.1个月(95%CI 13.42至40.56),铂类化疗组为11.22个月(95%CI 8.26至15.63),P=0.013。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。
  • 作者指出这些数据需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of the present analysis was to explore the efficacy of Bevacizumab (Bev) on survival outcome in advanced low grade serous ovarian cancer (LGSOC) both in first line and in recurrent setting. METHODS: In retrospective observational multicenter study, we described the outcome of LGSOC patients enrolled in the MITO 22 study and treated with chemotherapy (CT) with or without Bev. Patients receiving Bev in first-line or in recurrence were considered and compared with patients receiving CT alone (stage III and IV in first line; platinum based-CT in second line). Descriptive and survival analyses were performed for each group. RESULTS: Out of 128 patients included in MITO 22, 46 LGSOC patients receiving Bev in first line setting or at the time of first recurrence were identified. In first line, 30 patients received Bev + CT and 65 CT alone and the median PFS were 47.86 months (95% CI: 31.48 - NR) and 22.63 months (95% CI 15-39.24) (p-value 0.0392), respectively. In the recurrent setting, 16 patients who received Bev + CT were compared to 33 women treated with platinum-based CT alone. Median PFS were 37.1 months (95% CI: 13.42-40.56) and 11.22 months (95% CI: 8.26-15.63) (p-value 0.013), respectively. CONCLUSIONS: Our study suggests that Bev might be effective in LGSOC both at diagnosis and at the time of relapse. These data warrants further studies.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Musacchio L, Turinetto M, Arenare L, et al. Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial. Gynecol Oncol. 2023. PMID: 36965291. doi:10.1016/j.ygyno.2023.03.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。